In last trading session, Lyra Therapeutics Inc (NASDAQ:LYRA) saw 1.04 million shares changing hands with its beta currently measuring 0.16. Company’s recent per share price level of $0.09 trading at $0.0 or -0.43% at ring of the bell on the day assigns it a market valuation of $6.10M. That closing price of LYRA’s stock is at a discount of -6177.78% from its 52-week high price of $5.65 and is indicating a premium of 11.11% from its 52-week low price of $0.08. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.72 million shares which gives us an average trading volume of 1.15 million if we extend that period to 3-months.
For Lyra Therapeutics Inc (LYRA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Upright in the red during last session for losing -0.43%, in the last five days LYRA remained trading in the green while hitting it’s week-highest on Tuesday, 04/22/25 when the stock touched $0.09 price level, adding 9.82% to its value on the day. Lyra Therapeutics Inc’s shares saw a change of -55.14% in year-to-date performance and have moved 0.43% in past 5-day. Lyra Therapeutics Inc (NASDAQ:LYRA) showed a performance of -43.23% in past 30-days. Number of shares sold short was 2.41 million shares which calculate 2.74 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 0.5 to the stock, which implies a rise of 82.0% to its current value. Analysts have been projecting 0.5 as a low price target for the stock while placing it at a high target of 0.5. It follows that stock’s current price would drop -455.56% in reaching the projected high whereas dropping to the targeted low would mean a loss of -455.56% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.22% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 42.42% while estimates for its earnings growth in next 5 years are of 21.95%.
Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders
Insiders are in possession of 0.83% of company’s total shares while institution are holding 50.90 percent of that, with stock having share float percentage of 51.33%. Investors also watch the number of corporate investors in a company very closely, which is 50.90% institutions for Lyra Therapeutics Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at LYRA for having 12.76 million shares of worth $3.53 million. And as of 2024-06-30, it was holding 19.4892 of the company’s outstanding shares.
The second largest institutional holder is CITADEL ADVISORS LLC, which was holding about 4.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.2912 of outstanding shares, having a total worth of $1.32 million.
On the other hand, iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 2.37 shares of worth $0.22 million or 3.59% of the total outstanding shares. The later fund manager was in possession of 992.54 shares on Dec 31, 2024 , making its stake of worth around $91909.0 in the company or a holder of 1.51% of company’s stock.
